Enanta Pharmaceuticals, Inc.

Yuhan Corporation

Janssen Biotech, Inc.

Cytochroma Inc.

The Johns Hopkins University

Oscotec Inc.

Genosco

Byung-Chul Suh

Yat Sun Or

Xiaowen Peng

Hui Cao

Xuri Gao

Wei Li

Jorden Kass

Yao-Ling Qiu

Jaekyoo Lee

Paresh Salgaonkar

Jiajun Zhang

In Y Lee

Jong Sung Koh

Se-Won Kim

Ho-Juhn Song

Jaesang Lee

Scott D Kuduk

Gary H Posner

Jay A White

Jung-Ho Kim

Hong Woon Yang

Glenville Jones

Su Bin Choi

Jae Young Sim

Kenneth R Crawford

Kwan Hoon Hyun

Hyunjoo Lee

James Campbell Robertson

Marian C Bryan

Young Ae Yoon

Dong Sik Jung

So Young Hwang

Guoqiang Wang

Jung-ho Kim

Qiang Wang

Joseph D Panarese

Uttam Saha

Jang-Sik Choi

Dong-Sik Jung

Misong Kim

Sung-Ho Park

Gyu Jin Lee

Yung-Geun Choi

Byoungmoon Lee

Heung Bae Jeon

Hae-Jun Hwang

HeungBae Jeon

Steven M Silverman

Jae Kyoo Lee

Tae-Im Lee

Mark Hatcher

Paresh Devidas Salgaonkar

In Yong Lee

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Macrocyclic spiropyrrolidine derived antiviral agents

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

Compounds and compositions for modulating EGFR mutant kinase activities

Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R  (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Hepatitis B antiviral agents

Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

Substituted aminopyridine compounds as EGFR inhibitors

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R&#x2003;&#x2003;(I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound  which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I). 

Substituted pyrimidine compounds and their use as SYK inhibitors

Growing community of inventors

Lexington, MA, United States of America

Byung-Chul Suh